Purpose/Objectives: To assess fear of progression (FoP) in outpatients with chronic myeloid leukemia (CML) on oral tyrosine kinase inhibitors (TKIs).
Design: Prospective and descriptive.
Setting: A university-based outpatient cancer clinic in Wuerzburg, Germany.
Sample: 37 outpatients with CML on oral TKIs.